Senti Bio Advances SENTI-202 Registrational Trial Following FDA Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SNTI?
Source: Newsfilter
- FDA Meeting Outcome: Senti Bio successfully completed a Type B meeting with the FDA, clarifying the registrational development strategy for SENTI-202, marking a significant advancement in the treatment of acute myeloid leukemia (AML) and expected to expedite clinical trial implementation.
- Clinical Trial Data: In the Phase 1 trial, patients receiving NK cells from Donor X exhibited a 50% composite complete remission (cCR) rate (7/14), compared to only 12.5% (1/8) for non-Donor X patients, highlighting the significant impact of the Donor X attribute on efficacy.
- Manufacturing Strategy Optimization: All future manufacturing of SENTI-202 will utilize Donor X material, a choice that not only enhances NK cell cytotoxicity but also supports the allogeneic off-the-shelf usage of SENTI-202, strengthening its market competitiveness.
- Long-term Efficacy Observation: Among the 22 patients in the Phase 1 trial, SENTI-202 demonstrated durable MRD-negative responses, with all complete remission patients maintaining remission during follow-up, with the longest duration reaching over 21 months, further validating its potential as a treatment option for AML patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNTI
Wall Street analysts forecast SNTI stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.963
Low
12.00
Averages
12.50
High
13.00
Current: 0.963
Low
12.00
Averages
12.50
High
13.00
About SNTI
Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The Company is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Senti Bio Advances SENTI-202 Registrational Trial Following FDA Meeting
- FDA Meeting Outcome: Senti Bio successfully completed a Type B meeting with the FDA, clarifying the registrational development strategy for SENTI-202, marking a significant advancement in the treatment of acute myeloid leukemia (AML) and expected to expedite clinical trial implementation.
- Clinical Trial Data: In the Phase 1 trial, patients receiving NK cells from Donor X exhibited a 50% composite complete remission (cCR) rate (7/14), compared to only 12.5% (1/8) for non-Donor X patients, highlighting the significant impact of the Donor X attribute on efficacy.
- Manufacturing Strategy Optimization: All future manufacturing of SENTI-202 will utilize Donor X material, a choice that not only enhances NK cell cytotoxicity but also supports the allogeneic off-the-shelf usage of SENTI-202, strengthening its market competitiveness.
- Long-term Efficacy Observation: Among the 22 patients in the Phase 1 trial, SENTI-202 demonstrated durable MRD-negative responses, with all complete remission patients maintaining remission during follow-up, with the longest duration reaching over 21 months, further validating its potential as a treatment option for AML patients.
See More
Senti Biosciences Reports Q4 Losses, Misses EPS Estimates
- Earnings Miss: Senti Biosciences reported a Q4 non-GAAP EPS of -$0.53, missing estimates by $0.06, indicating challenges in profitability that could undermine investor confidence.
- Cash Position: As of December 31, 2025, Senti Bio held approximately $16.4 million in cash and cash equivalents, which, while providing some liquidity, raises concerns about capital efficiency and future funding needs.
- Market Reaction: The earnings miss may negatively impact Seeking Alpha’s Quant Rating on Senti Biosciences, prompting investors to reassess the company's growth potential in light of recent performance.
- Historical Financial Data: Historical earnings data for Senti Biosciences suggests that ongoing losses could exert pressure on its long-term strategic development, particularly in the highly competitive biotech sector.
See More
SENTI BIOSCIENCES REPORTS Q4 REVENUE OF $22,000
Quarterly Revenue Overview: The report highlights that the revenue for Q4 reached $22,000, indicating a significant financial performance.
Sector Performance: The analysis suggests that various sectors contributed to the overall revenue, showcasing diverse growth areas within the company.
See More
Senti Bio to Present at Global Healthcare Conference
- Conference Presentation: Senti Biosciences' CEO Timothy Lu is set to present at the Leerink Partners Global Healthcare Conference in Miami on March 9, 2026, showcasing the company's advancements in cell and gene therapies, which is expected to attract investor and industry attention.
- Platform Advantages: Leveraging its proprietary Gene Circuit platform, Senti Bio is developing next-generation cell and gene therapies aimed at precisely killing cancer cells while sparing healthy ones, thereby enhancing treatment safety and efficacy, which holds significant market potential.
- Clinical Stage Progress: The company's pipeline includes cell therapies targeting challenging liquid and solid tumors, with preclinical studies demonstrating the effectiveness of its Gene Circuits in both NK and T cells, indicating broad applicability and potential clinical value of its technology.
- Information Transparency: Senti Bio emphasizes communication with investors through its website and social media, ensuring timely updates and transparency of information, which enhances investor confidence and promotes public understanding of its technology.
See More
Senti Bio Participates in Cell & Gene Live Event on Innovative Therapies
- Technology Sharing: Senti Bio participated in the Cell & Gene Live virtual event on February 19, 2026, where it showcased its Gene Circuit-based cell therapy technology, emphasizing its advantages in precision and functionality aimed at advancing the design and development of cell therapies.
- Product Introduction: SENTI-202 is the first Logic Gated CAR-NK cell therapy product designed to target CD33 and FLT3 expressing hematologic malignancies, effectively eliminating leukemic cells while sparing healthy bone marrow cells, demonstrating significant therapeutic potential.
- Clinical Trial Progress: Senti Bio is currently enrolling adult patients for a Phase 1 clinical trial of SENTI-202 targeting relapsed/refractory hematologic malignancies, which, if successful, could become the first allogeneic treatment for AML/MDS, presenting substantial market opportunities.
- FDA Designation: SENTI-202 has received Orphan Drug and Regenerative Medicine Advanced Therapy designations from the FDA, indicating its potential in treating relapsed hematologic malignancies, thereby enhancing investor and market confidence.
See More
Senti Bio's SENTI-202 Clinical Data Shows Promising Results
- Clinical Trial Milestone: Senti Bio announced the completion of enrollment in its Phase 1 clinical trial for SENTI-202, marking a significant advancement in treating relapsed or refractory acute myeloid leukemia (R/R AML), which is expected to lay the groundwork for subsequent pivotal registration studies.
- Positive Clinical Data: At the American Society of Hematology (ASH) Annual Meeting, SENTI-202 demonstrated deep, MRD-negative, durable complete remissions with a favorable safety profile in heavily pretreated R/R AML patients, potentially boosting market confidence in this therapy.
- FDA Discussion Preparation: The company plans to engage with the FDA in the first half of 2026 to discuss the pivotal registration program for SENTI-202 in R/R AML and the evaluation of additional indications, including newly diagnosed AML and pediatric AML, indicating the company's focus on future market opportunities.
- RMAT Designation Advantage: SENTI-202 has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may expedite its development and review process, thereby providing patients with faster treatment options and enhancing the company's competitive position in the market.
See More
Senti Bio Advances SENTI-202 Registrational Trial Following FDA Meeting
- FDA Meeting Outcome: Senti Bio successfully completed a Type B meeting with the FDA, clarifying the registrational development strategy for SENTI-202, marking a significant advancement in the treatment of acute myeloid leukemia (AML) and expected to expedite clinical trial implementation.
- Clinical Trial Data: In the Phase 1 trial, patients receiving NK cells from Donor X exhibited a 50% composite complete remission (cCR) rate (7/14), compared to only 12.5% (1/8) for non-Donor X patients, highlighting the significant impact of the Donor X attribute on efficacy.
- Manufacturing Strategy Optimization: All future manufacturing of SENTI-202 will utilize Donor X material, a choice that not only enhances NK cell cytotoxicity but also supports the allogeneic off-the-shelf usage of SENTI-202, strengthening its market competitiveness.
- Long-term Efficacy Observation: Among the 22 patients in the Phase 1 trial, SENTI-202 demonstrated durable MRD-negative responses, with all complete remission patients maintaining remission during follow-up, with the longest duration reaching over 21 months, further validating its potential as a treatment option for AML patients.
See More
Senti Biosciences Reports Q4 Losses, Misses EPS Estimates
- Earnings Miss: Senti Biosciences reported a Q4 non-GAAP EPS of -$0.53, missing estimates by $0.06, indicating challenges in profitability that could undermine investor confidence.
- Cash Position: As of December 31, 2025, Senti Bio held approximately $16.4 million in cash and cash equivalents, which, while providing some liquidity, raises concerns about capital efficiency and future funding needs.
- Market Reaction: The earnings miss may negatively impact Seeking Alpha’s Quant Rating on Senti Biosciences, prompting investors to reassess the company's growth potential in light of recent performance.
- Historical Financial Data: Historical earnings data for Senti Biosciences suggests that ongoing losses could exert pressure on its long-term strategic development, particularly in the highly competitive biotech sector.
See More
SENTI BIOSCIENCES REPORTS Q4 REVENUE OF $22,000
Quarterly Revenue Overview: The report highlights that the revenue for Q4 reached $22,000, indicating a significant financial performance.
Sector Performance: The analysis suggests that various sectors contributed to the overall revenue, showcasing diverse growth areas within the company.
See More
Senti Bio to Present at Global Healthcare Conference
- Conference Presentation: Senti Biosciences' CEO Timothy Lu is set to present at the Leerink Partners Global Healthcare Conference in Miami on March 9, 2026, showcasing the company's advancements in cell and gene therapies, which is expected to attract investor and industry attention.
- Platform Advantages: Leveraging its proprietary Gene Circuit platform, Senti Bio is developing next-generation cell and gene therapies aimed at precisely killing cancer cells while sparing healthy ones, thereby enhancing treatment safety and efficacy, which holds significant market potential.
- Clinical Stage Progress: The company's pipeline includes cell therapies targeting challenging liquid and solid tumors, with preclinical studies demonstrating the effectiveness of its Gene Circuits in both NK and T cells, indicating broad applicability and potential clinical value of its technology.
- Information Transparency: Senti Bio emphasizes communication with investors through its website and social media, ensuring timely updates and transparency of information, which enhances investor confidence and promotes public understanding of its technology.
See More
Senti Bio Participates in Cell & Gene Live Event on Innovative Therapies
- Technology Sharing: Senti Bio participated in the Cell & Gene Live virtual event on February 19, 2026, where it showcased its Gene Circuit-based cell therapy technology, emphasizing its advantages in precision and functionality aimed at advancing the design and development of cell therapies.
- Product Introduction: SENTI-202 is the first Logic Gated CAR-NK cell therapy product designed to target CD33 and FLT3 expressing hematologic malignancies, effectively eliminating leukemic cells while sparing healthy bone marrow cells, demonstrating significant therapeutic potential.
- Clinical Trial Progress: Senti Bio is currently enrolling adult patients for a Phase 1 clinical trial of SENTI-202 targeting relapsed/refractory hematologic malignancies, which, if successful, could become the first allogeneic treatment for AML/MDS, presenting substantial market opportunities.
- FDA Designation: SENTI-202 has received Orphan Drug and Regenerative Medicine Advanced Therapy designations from the FDA, indicating its potential in treating relapsed hematologic malignancies, thereby enhancing investor and market confidence.
See More
Senti Bio's SENTI-202 Clinical Data Shows Promising Results
- Clinical Trial Milestone: Senti Bio announced the completion of enrollment in its Phase 1 clinical trial for SENTI-202, marking a significant advancement in treating relapsed or refractory acute myeloid leukemia (R/R AML), which is expected to lay the groundwork for subsequent pivotal registration studies.
- Positive Clinical Data: At the American Society of Hematology (ASH) Annual Meeting, SENTI-202 demonstrated deep, MRD-negative, durable complete remissions with a favorable safety profile in heavily pretreated R/R AML patients, potentially boosting market confidence in this therapy.
- FDA Discussion Preparation: The company plans to engage with the FDA in the first half of 2026 to discuss the pivotal registration program for SENTI-202 in R/R AML and the evaluation of additional indications, including newly diagnosed AML and pediatric AML, indicating the company's focus on future market opportunities.
- RMAT Designation Advantage: SENTI-202 has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may expedite its development and review process, thereby providing patients with faster treatment options and enhancing the company's competitive position in the market.
See More
